The c-erbB-3 gene is a recently identified member of the type I family of growth factor receptors. It is located on chromosome 12q13 and codes for a 180 000 molecular weight glycoprotein. The protein product shows considerable sequence homology to other members of the type I family of growth factor receptors, the epidermal growth factor receptor (EGFR) and the c-erbB-2 oncoprotein, especially in the tyrosine kinase domain (Lemoine et al., 1992; Rajkumar et al., 1993) .
Expression of both EGFR and the c-erbB-2 oncoproteins have been associated with established prognostic indicators and a poorer prognosis in human breast carcinoma (Sainsbury et al., 1985 (Sainsbury et al., , 1987 Nicholson et al., 1990; Grimaux et al., 1989; Walker et al., 1989; Wright et al., 1989; Gullick et al., 1991; Slamon et al., 1987) . The sequence homology of the c-erbB-3 oncoprotein to the EGFR and cerbB-2 oncoprotein has lead to interest in c-erbB-3 expression in breast cancer.
Using immunohistochemical techniques, c-erbB-3 expression in normal breast tissue has been shown to be weak to moderate (Prigent et al., 1992) . Expression in breast tumour tissue is heterogeneous. However, overexpression, defined as intensity greater than normal tissues, has been demonstrated to occur in approximately 13 to 23% of cases (Lemoine et al., 1992; Prigent et al., 1992) again using immunohistological techniques.
Although associations have been found between high expression of c-erbB-3, lymph node metastasis and c-erbB-2 expression, no other associations have been found with established prognostic indicators or prognosis (Lemoine et al., 1992; Gasparini et al., 1994) . This study used the RTJ1 antibody for immunocytochemistry to investigate c-erbB-3 expression and the relationship between overexpression and prognostic indicators and prognosis. Sections were incubated with the RTJ1 antibody at a 1:10 dilution. This dilution was shown to give optimal staining in pilot experiments. Binding of the primary antibody was demonstrated by a standard avidin-biotin complex techique; biotinylated goat anti-mouse immunoglobulin followed by preformed soluble complexes of avidin and biotinylated horseradish peroxidase (Dako). Diaminobenzidine was used as the chromogen with copper sulphate enhancement and haematoxylin was used as the counterstain. Sections were also processed in the absence of RTJ1 antibody to act as negative controls and tumours of known c-erbB-3 immunoreactivity were stained as positive controls on each run.
Methods
Staining was assessed according to the degree of cytoplasmic staining on a four-point scale: 0, negative; 1, weakly positive; 2, moderately positive; 3, strongly positive.
Owing to heterogeneous immunoreactivity within most sections, the whole tumour was systematically assessed by grading fields every 0.2 cm within the section. If the tumour area within the section was small or diffuse throughout the stroma then the whole slide was scanned and graded. The overall intensity for each tumour was taken to be that shown by the majority of fields. Blind reassessment of a random 15% of the sections in each series ensured consistency in assessment.
Adjacent normal breast epithelial tissue was also assessed. Immunoreactivity in normal tissue was found to be heterogeneous, and, if present, of weak or moderate intensity. For the purpose of this study only those tumours exhibiting strong positivity were considered to overexpress c-erbB-3.
Statistical analysis
Relationships between variables were sought using chisquared analyses. Survival data were examined by the lifetable method (Mantel -Cox). All statistical analyses were performed using SPSSX software.
Results
A variable degree of immunoreactivity was observed in breast tumours. Within the carcinomas staining was found to be heterogeneous and predominantly cytoplasmic with membrane staining seen in less than 1% of cases ( Figure 1 ). The majority of tumours in both series exhibited moderate immunoreactivity but a substantial proportion in both the primary and advanced series exhibited strong positivity (Figure 2 (Sainsbury et al., 1985 (Sainsbury et al., , 1987 Nicholson et al., 1990 (Slamon et al., 1987) . Further studies have supported this association (Wright et al., 1989; Gullick et al., 1991; Lovekin et al., 1991 ). An inverse association has also been demonstrated between c-erbB-2 expression and ER status (Slamon et al., 1987) .
The c-erbB-3 gene was first cloned by Kraus et al. in 1989 and subsequently by Plowman et al. in 1990 . Its protein product is a 180 kDa transmembrane glycoprotein that shows considerable sequence homology to the EGFR and the c-erbB-2 protein, especially in the tyrosine kinase domain.
A study examining c-erbB-3 protein expression in normal human adult and fetal tissues demonstrated that most developing human tissues, except haemopoietic tissues, express c-erbB-3 and expression is not restricted to proliferating cells. Normal adult breast tissue shows a moderately intense staining of luminal epithelial cells of breast acini and a weaker reactivity of basal myoepithelial cells. This normal distribution is distinctive and different from that observed with EGFR and c-erbB-2. Reactivity is predominantly cytoplasmic and no membrane reactivity of normal tissue has been observed in these early studies (Prigent et al., 1992) .
Poller et al. used a polyclonal antibody raised to the c-erbB-3 protein to examine c-erbB-3 expression in a variety of adenocarcinomas. C-erbB-3 protein expression was detected in a series of 13 out of 14 primary breast carcinomas. Expression of the c-erbB-3 protein was found to be a common event in adenocarcinomas but its role in neoplastic progression remained unclear (Poller et al., 1992) .
In a more detailed study of breast carcinoma, Lemoine et al. (1992) showed consistently higher levels of the c-erbB-3 oncoprotein in cell lines but a wide range of expression in resected primary human breast tumours. In the breast tumours overexpression was seen in 22% of cases, the predominant pattern being cytoplasmic with membrane immunoreactivity being seen in one case only. Investigation of associations with tumour size, histological grade, stage and C-erbB-3 i human breast carcioma A Travis et al   232 survival showed correlation only with lymph node metastatic disease. No relationship with overall prognosis was demonstrated. In our series. using the IgM monoclonal antibody RTJ1 (Rajkumar et al.. 1993) . we have examined the largest series of patients presenting with breast carcinoma to date, including 346 patients with primary operable breast cancer and 145 patients with advanced disease. Cytoplasmic reactivity was the predominant pattern seen and less than 1% of tumours showed positive membrane reactivity. As previously demonstrated by Lemoine et al.. the degree of expression varied (Lemoine et al.. 1992) . The majority of tumours expressed moderate immunoreactivity. Fifteen percent and 35% of cases in the primary and advanced series respectively demonstrated strong positive staining which for the purposes of this study was considered overexpression. as reactivity in normal breast epithelial tissue. although heterogeneous. was confined to negative. weak or moderate levels of intensity. Different levels of frequency of overexpression were identified in the two groups of patients in this study but this failed to reach statistical significance.
No significant associations were demonstrated between c-erbB-3 expression and survival in either patients with primary operable breast cancer or those with advanced disease and no correlation with DFI was found in the former group. In particular there was no relationship with lymph node status in this series which is in contrast to the study carried out by Lemoine et al. (1992) . In the patients with operable disease. however, an association was seen between greater intensities of immunoreactivity with RTJ1 antibody and both increased tumour size and a weaker association with poor prognostic type group. In addition those tumours which showed moderate or strong immunoreactivity with c-erbB-3 antibody appeared to be more likely to develop locally recurrent disease. The associations we report here have not been previously documented. Nevertheless, it seems unlikely that immunohistochemical assessment of c-erbB-3 expression will provide sufficiently powerful prognostic information to be clinically useful: the associations with other prognostic factors we describe here are based on differences in intensity of immunoreactivity rather than presence or absence of staining.
A recent study has demonstrated that the growth factor ligand heregulin binds to the c-erbB-3 receptor . The same group have also demonstrated little or no tyrosine kinase activity following stimulation and binding of heregulin with the c-erbB-3 receptor. However, in cells expressing both c-erbB-2 and c-erbB-3 a high-affinity binding site is generated and on stimulation produces unique tyrosine residues . This is in contrast to the interaction and complex formation between c-erbB-2 and cerbB-4 where both receptors have active tyrosine kinase components which are capable of autophosphorylation (Plowman et al., 1993) . The potential for type I tyrosine kinase receptors to produce different combinations of heregulin-stimulated heterodimeric complexes could explain some of the varied biological activities that have been demonstrated with this group of receptors (Carraway and Cantley, 1994) . We have found no association between overexpression of c-erbB-2 and c-erbB-3 assessed immunohistochemicallv.
In common with other published series we have demonstrated virtually ubiquitous cytoplasmic expression of c-erbB-3 protein at weak to strong levels. The c-erbB-3 gene sequence codes for transmembrane types of protein but membrane localisation of c-erbB-3 protein appears to be a rare phenomenon and is much lower in frequency than EGFR and c-erbB-2 proteins in invasive breast cancer. It is known that EGFR and c-erbB-2 are internalised by endocytosis after ligand binding. The predominant cytoplasmic localisation of c-erbB-3 protein could indicate internalised. non-functional or non-membrane-associated protein.
The c-erbB-3 protein may be an orphan receptor (Kraus et al.. 1993) but, if the parent of the orphan in terms of signalling were c-erbB-2 or c-erbB-4 as has recently been suggested. then the c-erbB-3 protein may be an important cofactor in the biological effects of type I growth factor receptors.
